pulmonary fibrosis alternative therapy

Alternative Therapy for Pulmonary Fibrosis

The Lung Institute offers patients with pulmonary fibrosis an alternative option for therapy in the form of stem cell procedures. We are proud to be the only stem cell clinic in the world that focuses solely on treating chronic lung disease, and as such can offer an unparalleled level of understanding and experience in the treatment of pulmonary conditions utilizing stem cells.

The Lung Institute offers two forms of stem cell therapy to treat pulmonary fibrosis:

  • Venous (blood-derived) — During this procedure, blood is drawn from the patient and then harvested, processed and reintroduced intravenously into the patient’s body.
  • Bone marrow — This procedure involves extracting a small amount of bone marrow from the patient. The stem cells are separated from the remaining cells, then reintroduced through an IV into the patient’s body.

Because our alternative therapy uses autologous stem cells, or stem cells derived from the patient’s own body, this treatment option has virtually no risk of complications or rejection. Both procedures are minimally invasive and performed on an outpatient basis over the course of two days. While there is currently no cure for pulmonary fibrosis, our stem cell therapy has shown to potentially slow the progression of lung disease, minimize inflammation in the lungs and improve a person’s quality of life. In fact, more than 80 percent of people who have undergone treatment at the Lung Institute have reported an improvement in their quality of life following the procedure.

For more information about the innovative stem cell procedures we offer as an alternative therapy to treat pulmonary fibrosis, call the Lung Institute team today at (800) 729-3065. One of our caring team members will gladly help determine your candidacy for stem cell treatment.

* All treatments performed at Lung Institute utilize autologous stem cells, meaning those derived from a patient's own body. No fetal or embryonic stem cells are utilized in Lung Institute's procedures. Lung Institute aims to improve patients' quality of life and help them breathe easier through the use of autologous stem cell therapy. To learn more about how stem cells work for lung disease, click here.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

Under current FDA guidelines and regulations 1271.10 and 1271.15, the Lung Institute complies with all necessary requirements for operation. The Lung Institute is firmly in accordance with the conditions set by the FDA for exemption status and conducts itself in full accordance with current guidelines. Any individual who accesses Lung Institute's website for information is encouraged to speak with his or her primary physician for treatment suggestions and conclusive evidence. All information on this site should be used for educational and informational use only.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and stem cell procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.